Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Vomiting 27Nausea 17Neoplasms 12Breast Neoplasms 4Multiple Myeloma 2Lymphoma 2Leukemia 2Hematologic Neoplasms 2Breast Neoplasms, Male 2Weight Loss 1Solid Tumors 1Sarcoma 1Rectal Neoplasms 1Pain 1Nausea With Vomiting Chemotherapy-Induced 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Inflammatory Breast Neoplasms 1Hematologic Diseases 1Glioma 1Genital Neoplasms, Female 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Anorexia 1

Interventions

Temozolomide 88Bevacizumab 49Radiotherapy 36Irinotecan 22Magnetic Resonance Spectroscopy 21Surgical Procedures, Operative 17Carboplatin 17Carmustine 15Radiation 13Nivolumab 11IL13-PE38 8Erlotinib Hydrochloride 8Thalidomide 7Radiotherapy, Intensity-Modulated 7Lomustine 7Imatinib Mesylate 7Everolimus 7Aminolevulinic Acid 7sargramostim 6Topotecan 6O(6)-benzylguanine 6Cyclophosphamide 6Chemotherapy, Adjuvant 6vandetanib 5temsirolimus 5fluorodopa F 18 5Vincristine 5Surveys and Questionnaires 5Radiosurgery 5Flucytosine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Glioma × Palonosetron × Clear all
NCT00900757 2019-08-28

Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide

Duke University

Phase 2 Completed
57 enrolled 10 charts
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡